Head-to-Head cancer drug battle shows promise for tough lymphoma cases
NCT ID NCT02684292
Summary
This study tested whether a drug called pembrolizumab works better than another drug, brentuximab vedotin, for people with Hodgkin lymphoma that has returned or hasn't responded to previous treatments. The trial involved 304 participants who received one of the two drugs for up to 35 treatment cycles. Researchers wanted to see which treatment helped patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.